Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 360 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Spray Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

NCT04408183
View directory record Official record
Conditions
SARS-CoV 2, Infection
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Philadelphia, Pennsylvania • Conroe, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

NCT00658918
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Hay Fever
Interventions
Ciclesonide nasal, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

NCT02597478
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires, Mental Ability Tests, Phone Call
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo

NCT01439815
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Fluticasone Propionate Nasal Spray, Saline Nasal Spray
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

NCT01550471
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 15 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Kovacaine Nasal Spray in Pediatric Subjects

NCT01952990
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 20, 2026, 9:22 AM EDT
Withdrawn Phase 4 Interventional

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

NCT06023368
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Num Vapocoolant Spray, EMLA Cream
Drug
Lead sponsor
Marianne Hutti
Other
Eligibility
4 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Market Potential of Carbon Dioxide Nasal Spray

NCT02113449
View directory record Official record
Conditions
Nasal Congestion
Interventions
Carbon Dioxide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chandler, Arizona • Pinellas Park, Florida • Paramus, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

NCT02155309
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Zomig - Treatment of Acute Migraine Headache in Adolescents

NCT01211145
View directory record Official record
Conditions
Migraine Headache
Interventions
Placebo, Zolmitriptan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Phoenix, Arizona • Fresno, California • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

NCT03633461
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-02 (simpinicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vapocoolant Spray Used Prior to Intravenous (IV) Insertions

NCT03054740
View directory record Official record
Conditions
Pain
Interventions
Gebauer Ethyl Chloride, Nature's Tears
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

NCT03235024
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

NCT01357356
View directory record Official record
Conditions
Nocturia
Interventions
SER120 (750 ng/day), SER120 (1000 ng/day), SER120 (1500 ng/day), Placebo
Drug
Lead sponsor
Serenity Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

NCT00578929
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
6 Years to 11 Years
Enrollment
2,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Kenilworth, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Nicotine Replacement and Counseling In Adolescents

NCT00625794
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine nasal spray, Smoking cessation counseling
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2008 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Assessment of SER120 in Patients With Nocturia

NCT00981682
View directory record Official record
Conditions
Nocturia
Interventions
SER120
Drug
Lead sponsor
Serenity Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

NCT00956254
View directory record Official record
Conditions
Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Fentanyl sublingual spray
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

NCT01715012
View directory record Official record
Conditions
Third Degree Burns, Diabetes
Interventions
ST266, Saline
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 20, 2026, 9:22 AM EDT